

CITATION REPORT

List of articles citing

Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis

DOI: 10.1016/j.ctrv.2013.09.004

Cancer Treatment Reviews, 2014, 40, 285-92.

Source: <https://exaly.com/paper-pdf/58954320/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
14	One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison. <i>Current Medical Research and Opinion</i> , 2015 , 31, 315-22	2.5	10
13	Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison. <i>International Journal of Cancer</i> , 2016 , 138, 1545-53	7.5	11
12	The pharmacogenomics of drug resistance to protein kinase inhibitors. <i>Drug Resistance Updates</i> , 2016 , 28, 28-42	23.2	19
11	Challenging Roadblocks to Cancer Cure. <i>Cancer Research</i> , 2016 , 76, 4924-30	10.1	3
10	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2016 , 122, 3336-3343	6.4	11
9	Treatment of chronic myelogenous leukemia. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 113-20	2.2	14
8	Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States. <i>Journal of Medical Economics</i> , 2017 , 20, 63-71	2.4	4
7	Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. <i>PLoS ONE</i> , 2017 , 12, e0171041	3.7	6
6	Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis. <i>European Journal of Cancer</i> , 2018 , 104, 9-20	7.5	15
5	Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis. <i>BMC Cancer</i> , 2019 , 19, 849	4.8	4
4	Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. <i>Acta Haematologica</i> , 2020 , 143, 204-216	2.7	3
3	Design, synthesis and biological evaluation of 2-methyl-(1,1dbiphenyl)-pyrimidine conjugates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020 , 30, 127328	2.9	4
2	First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020 , 4, 2723-2735	7.8	17
1	Advances in paediatric cancer treatment. <i>Translational Pediatrics</i> , 2014 , 3, 156-82	4.2	26